CD19 and non-Hodgkin lymphoma: Encouragingly, T cells expressing the CD19-CARs have achieved unprecedented therapeutic efficacy in malignant hematological diseases with up to 90% complete remission rate in ALL and more than 60% in non-Hodgkin's lymphoma (NHL) [2].